Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

As shown in Figure 2 and 3, the pooled SMDs for alogliptin 12.5 mg treated vs controls, and alogliptin 25 mg treated vs controls demonstrated a significant reduction in HbA1c in patients treated ...

Review the side-effects of Alogliptin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Get detailed information on Alogliptin, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...